Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
<i>Background and Objectives</i>: Atherosclerosis is a disease in the pathogenesis of which plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include osteopontin (OPN), osteoprotegerin (OPG), and metalloproteinases (MMPs), which are factors that may be re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/7/969 |
| _version_ | 1797417088208338944 |
|---|---|
| author | Michał Kosowski Marcin Basiak Marcin Hachuła Bogusław Okopień |
| author_facet | Michał Kosowski Marcin Basiak Marcin Hachuła Bogusław Okopień |
| author_sort | Michał Kosowski |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Atherosclerosis is a disease in the pathogenesis of which plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include osteopontin (OPN), osteoprotegerin (OPG), and metalloproteinases (MMPs), which are factors that may be responsible for the stabilization of atherosclerotic plaque. The aim of this study was to assess the effect of modern lipid-lowering therapy by using proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitor on the concentrations of these factors. <i>Materials and Methods</i>: The study included people suffering from dyslipidemia who were eligible to start alirocumab therapy. In this group, the concentrations of OPN, OPG, and MMPs were assessed before the initiation of therapy and after three months of its duration. <i>Results:</i> In the study, we observed a statistically significant reduction in the concentrations of OPN, OPG (<i>p</i> < 0.001), and metalloproteinase 2 (MMP-2) (<i>p</i> < 0.05) after the applied therapy. Moreover, we noticed that in the group of patients soon to start alirocumab therapy, the concentrations of these factors were higher compared to the control group (<i>p</i> < 0.001). <i>Conclusions</i>: The results of our study show that therapy with alirocumab significantly reduces the concentration of factors that affect atherosclerotic plaque vulnerability, which may explain their important role in reducing cardiovascular risk in patients undergoing this therapy. |
| first_indexed | 2024-03-09T06:14:53Z |
| format | Article |
| id | doaj.art-960d0193a9df4764ac96896a4c4fd607 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T06:14:53Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-960d0193a9df4764ac96896a4c4fd6072023-12-03T11:55:07ZengMDPI AGMedicina1010-660X1648-91442022-07-0158796910.3390/medicina58070969Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic PlaqueMichał Kosowski0Marcin Basiak1Marcin Hachuła2Bogusław Okopień3Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, PolandDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-752 Katowice, Poland<i>Background and Objectives</i>: Atherosclerosis is a disease in the pathogenesis of which plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include osteopontin (OPN), osteoprotegerin (OPG), and metalloproteinases (MMPs), which are factors that may be responsible for the stabilization of atherosclerotic plaque. The aim of this study was to assess the effect of modern lipid-lowering therapy by using proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitor on the concentrations of these factors. <i>Materials and Methods</i>: The study included people suffering from dyslipidemia who were eligible to start alirocumab therapy. In this group, the concentrations of OPN, OPG, and MMPs were assessed before the initiation of therapy and after three months of its duration. <i>Results:</i> In the study, we observed a statistically significant reduction in the concentrations of OPN, OPG (<i>p</i> < 0.001), and metalloproteinase 2 (MMP-2) (<i>p</i> < 0.05) after the applied therapy. Moreover, we noticed that in the group of patients soon to start alirocumab therapy, the concentrations of these factors were higher compared to the control group (<i>p</i> < 0.001). <i>Conclusions</i>: The results of our study show that therapy with alirocumab significantly reduces the concentration of factors that affect atherosclerotic plaque vulnerability, which may explain their important role in reducing cardiovascular risk in patients undergoing this therapy.https://www.mdpi.com/1648-9144/58/7/969PCSK-9 inhibitorsatherosclerotic plaquedyslipidemiaosteopontinosteoprotegerinmetalloproteinase 2 |
| spellingShingle | Michał Kosowski Marcin Basiak Marcin Hachuła Bogusław Okopień Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque Medicina PCSK-9 inhibitors atherosclerotic plaque dyslipidemia osteopontin osteoprotegerin metalloproteinase 2 |
| title | Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque |
| title_full | Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque |
| title_fullStr | Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque |
| title_full_unstemmed | Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque |
| title_short | Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque |
| title_sort | impact of alirocumab on release markers of atherosclerotic plaque vulnerability in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque |
| topic | PCSK-9 inhibitors atherosclerotic plaque dyslipidemia osteopontin osteoprotegerin metalloproteinase 2 |
| url | https://www.mdpi.com/1648-9144/58/7/969 |
| work_keys_str_mv | AT michałkosowski impactofalirocumabonreleasemarkersofatheroscleroticplaquevulnerabilityinpatientswithmixedhyperlipidemiaandvulnerableatheroscleroticplaque AT marcinbasiak impactofalirocumabonreleasemarkersofatheroscleroticplaquevulnerabilityinpatientswithmixedhyperlipidemiaandvulnerableatheroscleroticplaque AT marcinhachuła impactofalirocumabonreleasemarkersofatheroscleroticplaquevulnerabilityinpatientswithmixedhyperlipidemiaandvulnerableatheroscleroticplaque AT bogusławokopien impactofalirocumabonreleasemarkersofatheroscleroticplaquevulnerabilityinpatientswithmixedhyperlipidemiaandvulnerableatheroscleroticplaque |